Circulating tumor cells and circulating tumor DNA

Annual Review of Medicine

Volumn 63, Issue , 2012, Pages 199-215

  Alix Panabières, Catherine ^a,b,c   Schwarzenbach, Heidi ^d   Pantel, Klaus ^d  

^a HÔPITAL SAINT ELOI   (France)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c UNIV MONTPELLIER   (France)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Allelic imbalance; Cell free tumor DNA; Epigenetic alterations; Genetic alterations; Tumor cell dissemination

Indexed keywords

CIRCULATING TUMOR DNA; DNA; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADJUVANT THERAPY; BREAST CANCER; CANCER GENETICS; CANCER STAGING; CARCINOMA; CELL FREE SYSTEM; CIRCULATING TUMOR CELL; COLON CANCER; DISTANT METASTASIS; EPITHELIAL MESENCHYMAL TRANSITION; EUROPE; HUMAN; LUNG CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; TUMOR REGRESSION;

BREAST NEOPLASMS; CARCINOMA; COLONIC NEOPLASMS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASTIC CELLS, CIRCULATING; PROSTATIC NEOPLASMS;

EID: 84855979597     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-062310-094219     Document Type: Review

References (93)

1. Pantel K, Brakenhoff RH, Brandt B. 2008. Detection, clinical relevance, and specific biological properties of disseminating tumour cells. Nat. Rev. Cancer 8:329-40 (Pubitemid 351596394)
2. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-74
3. Aguirre-Ghiso JA. 2007. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7:834-46 (Pubitemid 350006258)
4. Pantel K, Alix-Panabìeres C, Riethdorf S. 2009. Cancer micrometastases. Nat. Rev. Clin. Oncol. 6:339-51
5. Kim MY, Oskarsson T, Acharyya S, et al. 2009. Tumor self-seeding by circulating cancer cells. Cell 139:1315-26
6. Aguirre-Ghiso JA. 2010. On the theory of tumor self-seeding: implications for metastasis progression in humans. Breast Cancer Res. 12:304
7. Pantel K, Brakenhoff RH. 2004. Dissecting the metastatic cascade. Nat. Rev. Cancer 4:448-56 (Pubitemid 38745530)
8. Schwarzenbach H, Hoon DS, Pantel K. 2011. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11:426-37
9. Cedar H, Bergman Y. 2009. LinkingDNAmethylation and histonemodification: patterns and paradigms. Nat. Rev. Genet. 10:295-304
10. Vona G, Sabile A, Louha M, et al. 2000. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am. J. Pathol. 156:57-63 (Pubitemid 30644439)
11. Pinzani P, Salvadori B, Simi L, et al. 2006. Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. Hum. Pathol. 37:711-18 (Pubitemid 43956539)
12. Zheng S, Lin HK, Lu B, et al. 2011. 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed. Microdevices 13:203-13
13. Tan SJ, Lakshmi RL, Chen P, et al. 2010. Versatile label free biochip for the detection of circulating tumor cells from peripheral blood in cancer patients. Biosens. Bioelectron. 26:1701-5
14. Bhagat AA, Hou HW, Li LD, et al. 2011. Pinched flow coupled shear-modulated inertial microfluidics for high-throughput rare blood cell separation. Lab Chip 11:1870-78
15. Moon HS, Kwon K, Kim SI, et al. 2011. Continuous separation of breast cancer cells from blood samples using multi-orifice flow fractionation (MOFF) and dielectrophoresis (DEP). Lab Chip 11:1118-25
16. Gascoyne PR, Noshari J, Anderson TJ, et al. 2009. Isolation of rare cells from cell mixtures by dielectrophoresis. Electrophoresis 30:1388-98
17. Andreopoulou E, Yang LY, Rangel KM, et al. 2011. Comparison of assay methods for detection of circulating tumor cells (CTCs) in metastatic breast cancer (MBC): AdnaGen AdnaTest BreastCancer Select/Detect versus Veridex CellSearch system. Int. J. Cancer. Epub ahead of print
18. Hofman V, Ilie MI, Long E, et al. 2011. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small cell lung carcinoma: comparison of the efficacy of the CellSearch assay and the isolation by size of epithelial tumor cell method. Int. J. Cancer 129:1651-60
19. Nagrath S, Sequist LV, Maheswaran S, et al. 2007. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450:1235-39
20. Maheswaran S, Sequist LV, Nagrath S, et al. 2008. Detection of mutations in EGFR in circulating lungcancer cells. N. Engl. J. Med. 359:366-77
21. Stott SL, Lee RJ, Nagrath S, et al. 2010. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci. Transl. Med. 2:25ra23
22. Stott SL, Hsu CH, Tsukrov DI, et al. 2010. Isolation of circulating tumor cells using a microvortexgenerating herringbone-chip. Proc. Natl. Acad. Sci. USA 107:18392-97
23. Saliba AE, Saias L, Psychari E, et al. 2010. Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays. Proc. Natl. Acad. Sci. USA 107:14524-29
24. Dharmasiri U, Njoroge SK, Witek MA, et al. 2011. High-throughput selection, enumeration, electrokinetic manipulation, and molecular profiling of low-abundance circulating tumor cells using a microfluidic system. Anal. Chem. 83:2301-9
25. Talasaz AH, Powell AA, Huber DE, et al. 2009. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc. Natl. Acad. Sci. USA 106:3970-75
26. Wang S, Owens GE, Tseng HR. 2011. Nano "fly paper" technology for the capture of circulating tumor cells. Methods Mol. Biol. 726:141-50
27. Pachmann K, Camara O, Kavallaris A, et al. 2008. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J. Clin. Oncol. 26:1208-15
28. Muller V, Alix-Panabíeres C, Pantel K. 2010. Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. Eur. J. Cancer 46:1189-97
29. Ledford H. 2011. Cancer theory faces doubts. Nature 472:273
30. Mani SA, Guo W, Liao MJ, et al. 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704-15 (Pubitemid 351636299)
31. Mego M, Mani SA, Cristofanilli M. 2010. Molecular mechanisms of metastasis in breast cancer-clinical applications. Nat. Rev. Clin. Oncol. 7:693-701
32. Mego M, Mani SA, Lee BN, et al. 2011. Expression of epithelial- mesenchymal transition-inducing transcription factors in primary breast cancer: the effect of neoadjuvant therapy. Int. J. Cancer. Epub ahead of print
33. Hou JM, Krebs M, Ward T, et al. 2011. Circulating tumor cells as a window on metastasis biology in lung cancer. Am. J. Pathol. 178:989-96
34. Gradilone A, Raimondi C, Nicolazzo C, et al. 2011. Circulating tumor cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. J. Cell Mol. Med. 15:1066-70
35. Raimondi C, Gradilone A, Naso G, et al. 2011. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res. Treat. 130:449-55
36. Konigsberg R, Obermayr E, Bises G, et al. 2011. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncol. 50:700-10
37. Lu J, Fan T, Zhao Q, et al. 2010. Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int. J. Cancer 126:669-83
38. Galanzha EI, Shashkov EV, Kelly T, et al. 2009. In vivo magnetic enrichment andmultiplex photoacoustic detection of circulating tumour cells. Nat. Nanotechnol. 4:855-60
39. Alix-Panabì eres C, Vendrell JP, Slijper M, et al. 2009. Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res. 11:R39
40. Alix-Panabìeres C, Vendrell JP, Pelle O, et al. 2007. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin. Chem. 53:537-39 (Pubitemid 46447957)
41. Krivacic RT, Ladanyi A, Curry DN, et al. 2004. A rare-cell detector for cancer. Proc. Natl. Acad. Sci. USA 101:10501-4 (Pubitemid 38955770)
42. Somlo G, Lau SK, Frankel P, et al. 2011. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res. Treat. 128:155-63
43. Ntouroupi TG, Ashraf SQ, McGregor SB, et al. 2008. Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope. Br. J. Cancer 99:789-95
44. Deng G, Herrler M, Burgess D, et al. 2008. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res. 10:R69
45. Scholtens TM, Schreuder F, Ligthart ST, et al. 2011. CellTracks TDI: An image cytometer for cell characterization. Cytometry A. 79:203-13
46. Markou A, Strati A, Malamos N, et al. 2011. Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. Clin. Chem. 57:421-30
47. Agrawal B, Krantz MJ, Parker J, et al. 1998. Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation. Cancer Res. 58:4079-81 (Pubitemid 28440559)
48. Schuettpelz LG, Link DC. 2011. Niche competition and cancer metastasis to bone. J. Clin. Invest. 121:1253-55
49. Shiozawa Y, Pedersen EA, Havens AM, et al. 2011. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Invest. 121:1298-312
50. Bellahcene A, Bachelier R, Detry C, et al. 2007. Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Breast Cancer Res. Treat. 101:135-48 (Pubitemid 46115420)
51. Garcia T, Jackson A, Bachelier R, et al. 2008. A convenient clinically relevant model of human breast cancer bone metastasis. Clin. Exp. Metastasis 25:33-42 (Pubitemid 351191224)
52. Le Gall C, Bellahcene A, Bonnelye E, et al. 2007. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res. 67:9894-902 (Pubitemid 47621238)
53. Paris PL, Kobayashi Y, Zhao Q, et al. 2009. Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer. Cancer Lett. 277:164-73
54. Attard G, Swennenhuis JF, Olmos D, et al. 2009. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 69:2912-18
55. Swennenhuis JF, Tibbe AG, Levink R, et al. 2009. Characterization of circulating tumor cells by fluorescence in situ hybridization. Cytometry A 75:520-27
56. Shaffer DR, Leversha MA, Danila DC, et al. 2007. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin. Cancer Res. 13:2023-29 (Pubitemid 46649868)
57. Leversha MA, Han J, Asgari Z, et al. 2009. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin. Cancer Res. 15:2091-97
58. Jiang Y, Palma JF, Agus DB, et al. 2010. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin. Chem. 56:1492-95
59. Smirnov DA, Foulk BW, Doyle GV, et al. 2006. Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas. Cancer Res. 66:2918-22
60. Watson MA, Ylagan LR, Trinkaus KM, et al. 2007. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Clin. Cancer Res. 13:5001-9 (Pubitemid 47502064)
61. Aktas B, Tewes M, Fehm T, et al. 2009. Stem cell and epithelial- mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 11:R46
62. Theodoropoulos PA, Polioudaki H, Agelaki S, et al. 2010. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 288:99-106
63. Reuben JM, Lee BN, Li C, et al. 2010. Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer. Breast J. 16:327-30
64. Gazzaniga P, Naso G, Gradilone A, et al. 2010. Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors. Int. J. Cancer 126:2437-47
65. Cristofanilli M, Budd GT, Ellis MJ, et al. 2004. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351:781-91 (Pubitemid 39095313)
66. Cohen SJ, Punt CJ, Iannotti N, et al. 2008. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 26:3213-21
67. de Bono JS, Attard G, Adjei A, et al. 2007. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin. Cancer Res. 13:3611-16 (Pubitemid 46955123)
68. de Bono JS, Scher HI, Montgomery RB, et al. 2008. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14:6302-9
69. Danila DC, Heller G, Gignac GA, et al. 2007. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res. 13:7053-58 (Pubitemid 350276887)
70. Liu MC, Shields PG, Warren RD, et al. 2009. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J. Clin. Oncol. 27:5153-59
71. Hayes DF, Cristofanilli M, Budd GT, et al. 2006. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res. 12:4218-24
72. Budd GT, Cristofanilli M, Ellis MJ, et al. 2006. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 12:6403-9 (Pubitemid 44799711)
73. De Giorgi U, Valero V, Rohren E, et al. 2009. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction inmetastatic breast cancer. J. Clin. Oncol. 27:3303-11
74. National Cancer Institute. 2011. Treatment decision making based on blood levels of tumor cells in women with metastatic breast cancer receiving chemotherapy. SWOG-S0500. http://clinicaltrials. gov/ct2/show/NCT00382018
75. Bidard FC, Mathiot C, Delaloge S, et al. 2010. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann. Oncol. 21:729-33
76. Riethdorf S, Muller V, Zhang L, et al. 2010. Detection and HER2 expression of circulating tumor cells prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro Trial. Clin. Cancer Res. 16:2634-45
77. Rack B, Schindlbeck C, Andergassen U, et al. 2010. Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: the SUCCESS Trial. J. Clin. Oncol. 28:7s
78. Xenidis N, Ignatiadis M, Apostolaki S, et al. 2009. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J. Clin. Oncol. 27:2177-84
79. Muller V, Stahmann N, Riethdorf S, et al. 2005. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin. Cancer Res. 11:3678-85 (Pubitemid 40685584)
80. Pantel K, Schlimok G, Braun S, et al. 1993. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J. Natl. Cancer Inst. 85:1419-24 (Pubitemid 23264351)
81. Stoecklein NH, Klein CA. 2010. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int. J. Cancer 126:589-98
82. Pantel K, Alix-Panabìeres C. 2010. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol. Med. 16:398-406
83. Klein CA. 2009. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 9:302-12
84. Fehm T, Hoffmann O, Aktas B, et al. 2009. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients byRT-PCRand comparison to status of bonemarrow disseminated cells. Breast Cancer Res. 11:R59
85. Braun S, Schlimok G, Heumos I, et al. 2001. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res. 61:1890-95 (Pubitemid 32692004)
86. Fehm T, Muller V, Aktas B, et al. 2010. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res. Treat. 124:403-12
87. Koyanagi K, Mori T, O'Day SJ, et al. 2006. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res. 66:6111-17
88. Matuschek C, Bolke E, Lammering G, et al. 2010. Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease. Eur. J. Med. Res. 15:277-86
89. Nawroz-Danish H, Eisenberger CF, Yoo GH, et al. 2004. Microsatellite analysis of serumDNAin patients with head and neck cancer. Int. J. Cancer 111:96-100 (Pubitemid 38859289)
90. Schwarzenbach H, Alix-Panabi ̀ eres C, Muller I, et al. 2009. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin. Cancer Res. 15:1032-38
91. Shaw JA, Brown J, Coombes RC, et al. 2011. Circulating tumor cells and plasma DNA analysis in patients with indeterminate early or metastatic breast cancer. Biomark Med. 5:87-91
92. Van derAuwera I, Elst HJ, Van Laere SJ, et al. 2009. The presence of circulating totalDNAand methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br. J. Cancer 100:1277-86
93. Wicha MS, Hayes DF. 2011. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J. Clin. Oncol. 29:1508-11